MultiCell Technologies Files Milestone Patent to Treat Cancer
Business Wire "US Press Releases "
SAN DIEGO--(BUSINESS WIRE)--
MultiCell Technologies, Inc. (OTCBB: MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced the filing of a milestone patent that provides a potential method for treating a range of malignant tumors using the Company's unique technologies to manipulate the immune system.
MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide. The new patent filing broadens protection of MultiCell's intellectual property portfolio, and further expands the Company's potential therapeutic development targets to include cancer.
The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
"The implications for this patent-pending technology are far-reaching and could someday help treat the millions of patients suffering from various cancers," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "We believe that this patent further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics."
The Company's technology platforms include TLR and T-cell targeting to modulate both the innate and adaptive immune systems, thus enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting.
MultiCell's new patent provides a method for treatment of a tumor after clinical diagnosis. The method involves the loading of an antigen presenting cell with at least one tumor associated T-cell epitope attached to an IgG backbone to form an Ig-peptide molecule followed by administration of the Ig-peptide molecule in vivo in conjunction with MultiCell's dsRNA TLR therapeutic.
MultiCell has a therapeutic pipeline with drug candidates already in various advanced stages of human clinical trials. These therapies include:
-- MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.
-- MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.
-- MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.
-- MCT-465 for the treatment of virus infection. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models.
SmallCapInsights.com Investment Newsletter Commences Editorial Coverage of MultiCell Technologies Following Recently Filed Patent on Cancer Treatment Tuesday October 3, 4:01 pm ET Editors Spotlight MCET's Strategy to Develop First-in-Class Drugs Based on Unique Immune-Modulation Technologies
SAN DIEGO--(BUSINESS WIRE)--SmallCapInsights.com, a leading investment newsletter committed to discovering tomorrow's smallcap breakthroughs, has announced the online release of a new installment of compensated coverage of MultiCell Technologies (the "Company") (OTCBB:MCET - News), an integrated biopharmaceutical company that uses proprietary immune system modulation technologies to discover and commercialize new therapeutics.
In an newsletter article released today, SmallCapInsights addresses MultiCell's most recent patent announcement--"Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," and provides investors with background on the Company and opinion on its progress and potential.
The articles states that "companies such as MultiCell Technologies (OTCBB:MCET - News) are on the cutting edge of bringing this type of biotech rocket science to the healthcare sector and, most importantly, to the benefit of millions of patients who suffer from debilitating maladies."
The article continues with a discussion of MultiCell's drug candidates, which are currently focused on treating afflictions such as Multiple Sclerosis (MS) type-1 diabetes and infectious disease such as influenza. With its recent patent filing, the Company has expanded its focus to the treatment of malignant tumors resulting from various forms of cancer. The Company has more than 40 issued, pending and applied-for patents covering its novel drug development technology.
Within the most recent Company press release, Dr. Stephen Chang, President and Chief Executive Officer of MultiCell, stated: "We believe that this patent filing further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics."
The article in SmallCapInsights continues: "The Company's first-in-class therapeutic pipeline currently includes MCT-125, a treatment for chronic fatigue in MS patients, MCT-175, for the treatment of relapsing-remitting MS, MCT-275 for the treatment of type-1 diabetes, and MCT-465, a TLR agonist adjuvant therapy targeting virus infection. MCT-465 has further demonstrated effectiveness in reducing HIV and HCV levels in animal models."
The potential for MultiCell's growth appears compelling, according to SmallCapInsights. The article explains, "These critical, yet underserved afflictions/markets have massive profit potential for utilizing novel therapeutics."
MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications and the production of therapeutic proteins, and is a leading producer of immortalized human hepatocyte cell lines needed by the biotechnology and pharmaceutical industries to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference/html.
The editors and publishers of SmallCapInsights.com have decades of direct experience both in the markets and in the newsletter genre as well as being avid students of the sector. The Companies we illuminate and represent are those we feel have the best chance of enhancing portfolio returns as we take them from initial profile to ongoing in-depth coverage. We aren't married to any space within the smallcap sector, just to those ideas and strategies that will make our opinions and observations a relevant starting point to your complete and ongoing due diligence. The good, the bad and the bizarre -and hopefully profitable--will populate our pieces. Our readers will first and foremost be our priority. Every article will include a detailed disclaimer. We are not analysts, but rather view our picks as an investor might: questioning, commenting and delivering our best opinions, be they pro or con. As well, in each piece we will highlight a technical opinion, which, though it can never be definitive, will serve to give readers a quick snapshot of our current T/A thoughts. For more information, visit http://www.smallcapinsights.com.
Editorial is provided by SmallcapInsights.com (``Smallcap'') to provide readers with information on publicly traded companies which have retained Smallcap to provide editorial commentary. Smallcap receives compensation for those services from the company, which consists of cash and/or securities of the company. Factual information is obtained from public filings and other sources deemed to be reliable; however, Smallcap takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete. Further, Smallcap and its employees and affiliates may own, or may purchase and sell, securities of the companies profiled. Smallcap undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled companies. As of September 26, 2006, SmallcapInsights.com receives from MultiCell Technologies an aggregate of US$21,500 for six months of editorial coverage.
Certain of the statements in this website may be considered forwarded looking statements. Smallcap makes no representation and provides no assurance or guaranty that such forward looking statements will be prove to be accurate. Statements of opinion and belief are those of the authors and/or editors of this website, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the companies profiled or any particular expertise in the industries or markets in which the profiled companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of profiled companies. Neither Smallcap nor anyone involved in the publication of this editorial is a registered investment adviser or broker/dealer. Smallcap makes no recommendation that the purchase of securities of companies profiled in this editorial is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. An investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this editorial should be construed as an offer or solicitation to buy or sell any securities of any profiled company.
MultiCell Technologies, Inc. Dr. Stephen Chang, 858.200.0598 MCETInvestor*MultiCelltech.com or SmallcapInsights.com Dr. John Faessel, 858-587-8590 editors*smallcapinsights.com or Trilogy Capital Partners (Financial Communications) Paul Karon, 800-592-6067 paul*trilogy-capital.com
Posts: 189 | Registered: Apr 2004
| IP: Logged |
MCET (.37) Announces Milestone Patent Issued by European Patent Office on Treatments for Autoimmune Diseases
Business Wire "US Press Releases "
SAN DIEGO--(BUSINESS WIRE)--
MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that the European Patent Office has granted the Company a key patent covering its next-generation technology targeting multibillion-dollar medical marketplace segments, including a range of serious autoimmune disorders such as diabetes and multiple sclerosis.
The patent issuance is a significant validation of the Company's business strategy to obtain broad, worldwide protection of its advanced immune modulation technologies and intellectual property. The Company recently announced that its IP portfolio crossed the key threshold of more than 50 issued or pending patents.
The patent, "Compositions for Treating Autoimmune Disease," leverages MultiCell's proprietary platform technologies in the science of modulating the human immune response to treat a range of serious diseases.
"We believe that this patent further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "We have already advanced our products into human clinical trials where researchers have reported extremely encouraging results showing the efficacy of our drug candidates to treat patients with MS and other conditions that desperately need new and substantially better therapeutic options."
MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide.
The newly issued patent is related to compositions for the effective endocytic presentation of immunosuppressive factors that are useful for the treatment of various disorders, such as autoimmune disorders. The Company's technology platforms include Toll-like Receptor signaling and T-cell targeting to modulate both the innate and adaptive immune systems. These technologies enable the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting.
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could" and "would." Examples of such forward-looking statements include statements regarding plans to develop new drug candidates, plans to expand intellectual property holdings, the ability of MultiCell to accelerate any of its therapeutic programs, or the ability of MultiCell to commercialize any drug candidates. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statements include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
Source: MultiCell Technologies, Inc.
-------------------- Now We Movin On Up!! Posts: 211 | From: Los Angelos | Registered: Oct 2004
| IP: Logged |